MedTrace Logo

Omacor for the Treatment of Vascular Dysfunction in Patients With Type 2 Diabetes Mellitus

NCT00328536 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2009-05-08

No results posted yet for this study

Summary

The purpose of the study is to determine whether a 6-week treatment with 4 g Omacor/day improves the baseline and postprandial endothelial function (after a high-fat meal) in patients with type 2 diabetes mellitus.

Conditions

Interventions

DRUG

Omacor

Sponsors & Collaborators

  • Heart and Diabetes Center North-Rhine Westfalia

    collaborator OTHER

  • Solvay Pharmaceuticals

    collaborator INDUSTRY

  • Ruhr University of Bochum

    lead OTHER

Principal Investigators

  • Diethelm Tschoepe, MD, Prof. · Heart and Diabetes Center North-Rhine Westfalia

  • Alin Stirban, MD · Heart and Diabetes Center North-Rhine Westfalia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00328536 on ClinicalTrials.gov